Optiscan Imaging

Optiscan Imaging LT Debt/Equity

The Long-Term Debt to Equity Ratio of Optiscan Imaging (OIL.AX) as of Oct 25, 2026 is 0.17.

LT Debt/Equity

0.17

Last updated:

Long-Term Debt to Equity Ratio of Optiscan Imaging is 2025 0.17 . Long-Term Debt to Equity Ratio of Optiscan Imaging was 2024 0.00 . It decreases by % higher compared to the previous year.

The Optiscan Imaging LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2018
0.00 AUD
Jan 1, 2019
0.00 AUD
Jan 1, 2020
0.42 AUD
Jan 1, 2021
0.05 AUD
Jan 1, 2022
0.06 AUD
Jan 1, 2023
0.06 AUD
Jan 1, 2024
0.00 AUD
Jan 1, 2025
0.17 AUD
The Optiscan Imaging LT Debt/Equity history
YEARLT Debt/EquityYoY
0.17—
0.00-100.00%
0.06+4.93%
0.06+16.47%
0.05-88.38%
0.42—
0.00—
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Optiscan Imaging Stock analysis

What does Optiscan Imaging do? Optiscan Imaging Ltd is an Australian company specializing in the development and commercialization of advanced imaging technologies. The company was founded in 1994 and is headquartered in Notting Hill, a suburb of Melbourne. Optiscan was originally established as a spin-off company from Monash University to enable the commercial application of a groundbreaking technology called confocal microscopy. However, over the years, the company has expanded into other imaging technologies and now offers a wide range of products and services. Optiscan's business model involves developing and bringing to market innovative technologies that can be used in biomedical research and clinical diagnostics. The company works closely with research institutions and companies in various industries to develop customized imaging solutions. Optiscan offers a wide range of products, including confocal microscopes, multiphotonic microscopes, real-time imaging systems, and Raman spectrometers. These products are used in various application areas such as cancer research, neurobiology, cell biology, and materials science. Another important area for Optiscan is veterinary imaging. The company has developed a product line for veterinary medicine that is used by veterinarians and researchers around the world. Optiscan's imaging systems enable veterinarians to obtain precise and detailed images of animals to enable better diagnosis and treatment. Optiscan also operates a service department that offers customized imaging solutions to customers. The company provides services such as image processing, data analysis, and prototype development. Overall, Optiscan has become one of the leading providers of imaging technologies in Australia and globally over the past decades. The company has a long history of collaboration with leading research institutions and companies worldwide and remains committed to developing innovative solutions for the challenges of biomedicine and imaging. Optiscan Imaging is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Optiscan Imaging stock

Long-Term Debt to Equity Ratio of Optiscan Imaging is 0.17 in 2025.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Optiscan Imaging since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Optiscan Imaging with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Optiscan Imaging

All Key Metrics — Optiscan Imaging